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ABSTRACT 
The neuroleptic drug thioridazine has been recently repositioned as possible antitubercular 
drug. Thioridazine showed antitubercular activity against drug resistant mycobacteria but it is 
endowed with adverse side effects. A small library of thioridazine derivatives has been 
designed through the replacement of the piperidine and phenothiazine moieties, with the aim 
to improve the antitubercular activity and to reduce the cytotoxic effects. Among the resulting 
compounds, the indole derivative 12e showed an antimycobacterial activity significantly 
better than thioridazine and a cytotoxicity 15-fold lower. 
 
1. INTRODUCTION 
According to the recent World Health Organization annual report, tuberculosis (TB) remains 
one of the deadliest communicable infections.[1] Nearly one third of the worldwide 
population is latently infection with Mycobacterium tuberculosis (MTB), the etiological agent 
of tuberculosis in humans, and almost 9 million people develop active TB infections per 
annum. In addition, 14.8% of global TB patients are co-infected with HIV and can be 
credited as one of the most common causes of death among AIDS patients.[2,3] This global 
scenario is due to many causes including the lack of rapid diagnostic tools, the non-
compliance of hospitalised patients to the 6-12 months multidrug therapy and institutions 
lacking the proper drug regimens to treat all the people infected.[4] As a consequence of these 
transgressions, and after half a century of little to no innovation in the field, MTB have 
developed multi-drug resistant (MDR),[5-7] extensively-drug resistant (XDR) [8] and totally-
drug resistant (TDR) [9] strains, which are resistant to almost all the known available drugs. 
In 2012, the quinoline derivative bedaquiline [10-11] became the first new drug launched in 
the market in the last 40 years, since the discovery of rifampin. Currently a number of lead 
molecules are in clinical trials, such as the diamine SQ109,[12] the fluoroquinolone 
gatifloxacin [13] and the linezolid.[14] However, the conventional therapeutic approach 
potentially exacerbates the incidence of new MDR-TB strains and therefore it is inevitable 
that MTB will evolve resistance against these novel drugs.[15-16]  
Conventional drug discovery approaches need the identification of a specific target for the 
development and optimization of a specific molecule. However, it is well known that singular 
mutations of the targets active site could result in the nullification of drug activity.[17] The 
current treatment of TB involves the administration of several drugs simultaneously, this 
reduces the incidence of resistant MTB strains by avoiding single point mutations resistances 
against singular treatments. However, several side effects and poor patient compliance are 
associated with the present multiple therapy. A potentially successful approach to defeat TB is 
to discover a drug capable of inhibiting multiple MTB targets simultaneously whilst also 
retaining activity against MDR and latent TB with an ultimate objective of shortening the 
current TB regimens.  
Thioridazine (TZ) 1, a long established neuroleptic drug, has been recently repositioned as 
anti-tubercular drug finding application in the treatment of MDR-TB.[18-19]
 
TZ is currently 
used in therapy as a third line anti-tubercular drug due to the side-effects on the central 
nervous system and cardiovascular system which restrict its clinical use.[20] Despite the 
mechanism of action of TZ having not been fully elucidated, recent studies showed that it 
inhibits efflux pumps in mycobacteria and alters the cell-envelope permeability of MTB.[21-
23]
 
Furthermore, TZ 1 is able to affects the physiology of alveolar macrophages, enhancing 
the retention of potassium ions and promoting the acidification of phagolysosomal 
vacuole,[24] finally leading to the degradation of intramacrophagic MTB.  
Despite the chemistry and structure-activity relationship (SAR) properties of TZ, and related 
neuroleptic drugs, having been widely investigated in the past, to the best of our knowledge 
no drug derivatization and optimization studies have been carried out on TZ analogues as 
inhibitors of MTB. 
Herein, we report the synthesis, biological evaluation and SAR studies of a narrow library of 
novel TZ derivatives. In particular, we aimed at the design and identification of novel TZ 
analogues with improved activity against TB and MDR-TB strains as well as reduced 
cytotoxic effects. Three series of derivatives were planned in order to explore the chemical 
space around the TZ nucleus, as shown in Figure 1. In the first series, the N-methyl 
substituent on the piperidine ring was removed or replaced with different alkyl groups to 
evaluate its importance for anti-tubercular activity. In the second series, the piperidine ring of 
TZ was replaced with different aliphatic heterocyles, keeping fixed the distance between the 
piperidine nitrogen and the phenothiazine ring. 
 Figure 1. General structures of the thioridazine analogues 
The role of the thiomethyl group attached to the phenothiazine ring was also investigated in 
this series. Finally, in the third series the phenothiazine core, which is responsible for the 
main side effects on the nervous system, was replaced with different heteroaromatic rings, 
with the aim to reduce the toxicity of the molecule.  
2. RESULTS AND DISCUSSION 
2.1 Chemistry 
 
Scheme 1. Synthesis of analogues 4a-c. Reagents and conditions: i. 1-chloro-ethyl-
chloroformate, DCE, TEA, reflux, 12 h; ii. MeOH, reflux, 12 h; iii. NaBH(AcO)3, THF, 
AcOH, benzaldehyde for 4a, or propionaldehyde for 4b, or acetone for 4c. 
A series of N-substituted derivatives 4a-c was first synthesised. TZ was successfully 
demethylated by treatment with 1-chloro-ethyl-chloroformate in refluxing DCE [25] followed 
by hydrolysis with MeOH under reflux, leading to derivative 3. Reductive amination of 3 
with different aldehydes/ketones led to the final N-alkyl-derivatives 4a-c in good yields (62-
68%). Scheme 1.  
 
Table 1. Synthesis of the compounds 7a-i and 9a-b. 
 
Reagents and conditions: i. 1-bromo-3-chloropropane, NaH, DMF, r.t., 12 h; ii. amine, 
DIPEA, NaI, DMF, 150 °C, 3 h; iii. 2-chloroacetyl chloride, NaH, DMF, r.t., 12 h; iv. amine, 
NaH, DMF, 150 °C. 
Cmpd R Amine/R1 Cmpd R  
7a H 
 
7g SMe 
 
7b H 
 
7h Cl 
 
7c SMe 
 
7i Cl 
 
7d SMe 
 
9a SMe 
 
7e SMe 
 
9b SMe 
 
7f SMe 
 
   
 A second series of derivatives where the piperidine ring was replaced with different 
piperazine and thiomorpholine groups was then synthesised (Table 1). In addition, the thio-
methyl substituent on the phenothiazine ring was removed or replaced with chlorine, to 
evaluate its importance for the antitubercular activity.  
In particular, the chlorine substituent was chosen on the basis of similarity with 
chlorpromazine, a phenothiazine derivative closely related to TZ whose efflux pumps 
inhibitory activity is well known. In detail, the phenothiazines 5a-c were first reacted with 1-
bromo-3-chloropropane to yield the chloroderivatives 6a-c which were in turn treated with 
different piperazines and with thiomorpholine to yield the desired products 7a-i. The thio-
methyl-phenothiazine 5a was also reacted with 2-chloroacetyl chloride leading to 8, which 
was in turn converted into derivatives 9a-b by treatment with methylpiperazine or piperidine. 
 
Scheme 2. Synthesis of analogues 12, 13 and 16. Reagents and conditions: i. (Boc)2O, 
Na2CO3(aq)/DCM, r.t., 12 h; ii. PPh3, CBr4, DCM, r.t., 2 h; iii. Heterocycle, NaH, NaI, DMF, 
r.t., 12 h; iv. HCl/EtOAc, r.t., 24 h; v. CH2CO, NaBH(AcO)3, THF, AcOH, r.t., 24 h; vi.1-
bromo-3-chloropropane, NaH, DMF, r.t., 12 h; vii. N-methyl-piperazine, DIPEA, NaI, DMF, 
150 °C, 3 h. 
Finally, the third series of compounds bearing the ethyl-piperidine chain of TZ bound to 
different aromatic heterocycles was synthesised. Scheme 2. 2-(Piperidin-2-yl)ethanol 10 was 
converted into the Boc-bromoderivative 11 by treatment with (Boc)2O followed by reaction 
with CBr4. Different heteroaromatic compounds (namely phenothiazine, 2-Cl-phenothiazine, 
carbazole, indole, and benzimidazole) were then alkylated with 11 and the resulting 
intermediates were deprotected with TFA yielding the 12a-e series of compounds. N-
methylation of 12 through reductive amination led to the methyl derivatives 13a-d.[26] 
Finally, 16, bearing an indole nucleus and a piperazine ring as the aliphatic side chain, were 
synthesised. Indole 14 was converted into the N-chloro-propyl derivative 15, which yielded 
the final compound 16 after treatment with N-methyl-piperazine. 
2.2. Biological evaluation 
All the compounds were initially evaluated for their activity against a panel of non-
pathogenic mycobacteria strains (namely, M. smegmatis mc
2
155, M. bovis BCG and M. 
tuberculosis mc
2
7000, as shown in Table 2).  
 
Table 2. Activity of TZ derivatives on mycobacterium species (expressed as g/mL). 
Cmpd 
M. smegmatis 
mc
2
 155 
M. bovis 
BCG 
M. tuberculosis MDR-TB 
mc
2
7000 H37Rv 
Susc. 
(CF73) 
CF104 CF81 
TZ 1 16 16 8 10 8 11 10 
3 16 8 8 100 >100 >100 >100 
4a 16 8 8 >100 37 32 44 
4b >64 64 64 45 - - - 
4c >64 >64 >64 - - - - 
7a 64 64 27 100 >100 >100 >100 
7b >64 >64 >64 - - - - 
7c 32 8 27 69 27 23 33 
7d >64 >64 >64 - - - - 
7e >64 >64 >64 - - - - 
7f 64 64 64 - - - - 
7g 4 >64 >64 43 98 20 48 
7h >64 >64 >64 - - - - 
7i >64 >64 >64 - - - - 
9a >64 >64 >64 - - - - 
9b - - - >100 >100 72 >100 
12a >64 >64 >64 >64 47 >64 58 
12b 16 5.3 4 26 11 19 11 
12c >64 >64 >64 - - - - 
12d >64 >64 >64 100 >100 >100 >100 
12e 1.6 64 - 2.9 1 10 4 
13a 32 64 16 >64 47 >64 58 
13b 16 8 8 19 16 16 12 
13c >64 >64 64 60 39 48 46 
13d >64 >64 >64 - - - - 
16 >64 >64 >64 - - - - 
INH 4 0.063 0.125 0.03 0.03 >25 >25 
RIF - - - 0.3 8 >25 >25 
 
A SAR analysis showed that removal of the methyl group of thioridazine did not affect the 
activity, the desmethyl-thioridazine 3 showing an activity similar to that of 1. Also the 
introduction of a benzyl chain as in 4b maintained a similar activity. On the other hand, the 
replacement of the piperidine-ethyl moiety with alkyl chains bearing piperazine or 
thiomorpholine rings as in 7 and 9 led to a dramatic decrease of antimycobacterial activity, 
with the only exception of the bulky derivative 7g which showed a MIC = 4 g/mL on M. 
smegmatis. Moreover, removal of the methylthio substituent of 1 and 3 (as in 13a and 12a), 
as well as replacement of the phenothiazine scaffold with different heterocyclic moieties (as 
in 13c-d and 12c-d) led to a significant loss in activity.  
 
Table 3. Cytotoxicity of compounds 1, 12b, 12e, 13b expressed as g/mL and Selectivity 
Index expressed as absolute number 
Cmpds IC50 MRC-5  SI
a
 
TZ 1 8.2 g/mL 1 
12b 10 g/mL 0.9 
12e 15 g/mL 15 
13b 13 g/mL 0.8 
a
Selectivity index is calculated as the ratio between the M. tuberculosis Susc. (CF73) MIC 
and the MRC-5 IC50. 
 
On the contrary, replacement of the same SMe group with a chloride group (as in 12b and 
13b), as well as replacement of the entire phenothiazine moiety with an indole nucleus as in 
12e resulted in compounds with an antimycobacterial activity comparable to or better than 
that of 1 and 3. In particular, the chloro-phenothiazine derivative 12b showed a good activity 
against M. bovis BGC and M. tuberculosis mc
2
7000 strains with MIC = 5.3 g/mL and 4 
g/mL, respectively. Similarly, the methylated analogue 13b retained a 8 g/mL MIC value. 
Interestingly, the indole derivative 12e proved to be highly active against M. smegmatis with 
MIC = 1.6g/mL. 
The most promising compounds were then assayed against the pathogenic H37Rv strain, the 
drug-susceptible CF73 clinical isolate, and two MDR- clinical isolates (CF104 and CF81). 
Also in this case, 12b, 12e, and 13b showed the best results. In particular, the chloro-
derivatives 12b and 13b had an activity toward the CF73 and the MDR strains similar to that 
of 1 in the same range of concentrations (8-16 g/mL). The indole derivative 12e proved to 
be the best compound of the series, with an increased activity against both H37Rv and CF73 
strains (2.9 and 1 g/mL, respectively, in comparison to 10 and 8 g/mL found for 1). 
Moreover, 12e also showed a similar profile against MDR-CF104 (10 vs 11 g/mL) and a 
slightly improved activity against MDR-CF81 (4 vs 10g/mL). These data suggest that the 
presence of a secondary amine on the piperidine side chains could be beneficial for the anti-
tubercular activity, as also observed in our previous work.[27]  
Finally, to prove the effectiveness of the most active compounds, their cytotoxicity was 
evaluated on MRC-5 cells. As a result, 12e showed a selectivity index 15 fold higher than 
that of TZ (Table 3). 
Finally, the effect of TZ derivatives on the efflux pumps of the model surrogate organism M. 
smegmatis was tested in order to understand the mode of action of the new compounds. 
Efflux pump inhibition (EPI) is determined using a whole-cell-based assay which interrogates 
the total activity of the diverse sets of efflux pumps present in the cell. The EPI assay showed 
that some TZ derivatives are endowed with a good efflux pump inhibitory activity. However, 
there is a weak correlation between inhibition of bacterial growth and efflux pump inhibtion. 
The compounds 12b and 12e which showed the most promising antimycobacterial activity 
proved to be poor efflux pump inhibitors (Figure 2). These compounds could interfere with 
the cell-envelope permeability, as already hypothesized for 1,[23] by means other than 
inhibiting efflux pumps. On the other hand, the piperazine derivatives 7a and 7c which did 
not show antimycobacterial activity, were found to inhibit efflux pumps better than the 
reference chlorpromazine. This indicates that these compounds have the potential to reverse 
multidrug resistance and could be promising candidates for inclusion in a combination 
therapy regimen owing to synergistic combinations.  
 
 Figure 2. Efflux pump inhibition assay. Graphs showing the accumulation of ethidium 
bromide (EtBr) within M. smegmatis cells in the presence of selected compounds and positive 
(verapamil VP and chlorpromazine CPZ) and negative (1× PBS) controls. Low to very high 
inhibition of efflux (as a representation of an increased level of EtBr accumulation) are 
shown by relative fluorescent units. The experiments were performed in triplicate (n = 3), and 
the graph is plotted using the average values obtained. 
 
3. CONCLUSIONS 
A classical medicinal chemistry approach has been applied to design and synthesise a narrow 
library of thioridazine derivatives by structural changes made on three different molecular 
portions. Antimycobacterial activity of the resulting compounds showed that the piperidine-
ethyl side chain is required for inhibit non-pathogenic, pathogenic and MDR mycobacterial 
strains. Moreover, the SMe-phenothiazine scaffold of 1 could be only replaced with the Cl-
phenothiazine analogue or simplified into an indole moiety. The most active compound 12e, 
bearing a demethylated piperazine ring in addition to an indole heterocycle, showed an 
activity profile better than that of 1 and a cytotoxicity about 15-fold lower toward MRC-5 
cells. 
 
4. MATERIAL AND METHODS 
Chemistry. Materials and Methods.  
1
H NMR and 
13
C NMR spectra were recorded on JEOL Delta-270 or JEOL ECS-400 
spectrometers operating at the frequencies indicated. Chemical shift (δ) are in ppm, 
referenced to tetramethylsilane. Coupling constants (J) are reported in hertz and rounded to 
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0.5 Hz. Splitting patterns are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet 
(q), multiplet (m), broad (br) or some combination of them. Infrared spectra were obtained 
using a Durascope diamond ATR system. Mass spectra (HRMS) were recorded at the EPSRC 
National Mass Spectrometry Service Centre on a Thermo Scientific LTQ Orbitrap XL mass 
spectrometer using low-resolution ESI or high-resolution nano ESI techniques. The purity of 
the compounds was assessed by reverse-phase liquid chromatography coupled with a mass 
spectrometer (Agilent series 1100 LC/MSD) with a UV detector at k = 254 nm and an 
electrospray ionization source (ESI). HPLC analyses were performed at 0.4 mL/min flow rate 
and using a binary solvent system of 95:5 methyl alcohol/water. All the solvents were of 
HPLC grade. Mass spectra were acquired in positive mode scanning over the mass range of 
50−1500. The following ion source parameters were used: drying gas flow, 9 mL/min; 
nebulize pressure, 40 psig; and drying gas temperature, 350 °C. All target compounds 
possessed a purity of ≥95%, as verified by HPLC analyses. TLC was performed using 
commercially available precoated plates and visualized with UV light at 254 nm; KMnO4 
was used to reveal the products. Flash column chromatography was carried out using 
Fluorochem Davisil 40−63 μm, 60 Å. All reactions were conducted under a nitrogen 
atmosphere in oven-dried glassware unless stated otherwise. THF was distilled under 
nitrogen from sodium using a benzophenone indicator. Dichloromethane was purchased from 
Aldrich. All other solvents and commercially available reagents were used as received. 
 
Synthesis of 1-chloroethyl 2-(2-(2-(methylthio)-10H-phenothiazin-10-
yl)ethyl)piperidine-1-carboxylate (2) 
Thioridazine (1) (3.87 mmol, 1 eq.) was dissolved in a round bottomed flask containing dry 
DCE (20 mL) and TEA (7.74 mmol, 2 eq.). The mixture was stirred at r.t. for 20 minutes 
before that 1-chloroethyl chloroformate (7.74 mmol, 2 eq.) was added to the solution. The 
mixture was left under N2 atmosphere at reflux for 12h. Then, the reaction mixture was 
quenched with 10 mL of water and extracted twice with 20 mL of EtOAc. The combined 
organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure giving a yellow-brown crude oil. The crude product was purified by chromatography 
on silica gel, using hexane/EtOAc (4:1) as eluent.  
Yield: 84%. 
1
H NMR (400 MHz CDCl3) δ 7.13-7.01 (m, 2H), 7.01-6.90 (m, 1H), 6.89-6.60 
(m, 4H), 6.59-6.29 (m, 1H), 4.20-3.90 (m, 1H), 3.90-3.60 (m, 2H), 2.90-2.74 (m, 1H), 2.74-
2.57 (m, 1H), 2.36 (s, 3H), 2.25-2.04 (m, 1H), 1.77-1.60 (m, 3H), 1.58-1.16 (m, 7H) ppm. 
13
C 
NMR (100 MHz CDCl3) δ 152.9, 145.0, 137.9, 127.8, 127.7, 127.4, 122.8, 121.0, 114.5, 
83.4, 49.9, 44.5, 39.8, 29.1, 27.8, 25.4, 19.1, 16.5, 14.3 ppm. LRMS m/z (ES+) m/z: 463 
[M+H]
+ 
 
Synthesis of 2-(methylthio)-10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine (3) 
Derivative 2 (3.84 mmol, 1 eq.)  was dissolved in MeOH (20 mL) and the solution was stirred 
at reflux for 12h then the reaction mixture was concentrated by reduced pressure evaporation. 
Then, the reaction mixture was quenched with 20 ml of water and extracted twice with 20 mL 
of EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure giving a yellow-brown crude oil. The obtained product 3 
was purified by chromatography on silica gel, using EtOAc/MeOH/TEA (3.9:1:0.1) as eluent.  
Yield: 85% 
1
H NMR (400 MHz CDCl3) δ 9.25 (br. s., 1H), 7.20-7.08 (m, 2H), 7.03 (d, J = 
6.9 Hz, 1H), 6.90 (d, J = 7.3 Hz, 2H), 6.82 (m, 2H), 4.13-3.93 (m, 2H), 3.29 (d, J = 12.8 Hz, 
1H), 3.02 (m, 1H), 2.68 (t, J = 12.1 Hz, 1H), 2.46 (s, 3H), 2.18-2.05 (m, 1H), 1.90-1.75 (m, 
3H), 1.75-1.53 (m, 3H), 1.44-1.28 (m, 1H) ppm. 
13
C NMR (100 MHz CDCl3) δ 145.9, 144.4, 
138.3, 127.8, 127.7, 127.7, 125.9, 123.2, 122.5, 121.2, 116.3, 114.5, 55.7, 44.7, 43.7, 30.7, 
28.8, 22.5, 22.2, 16.4 ppm. LRMS m/z (ES+) m/z: 357 [M+H]
+ 
 
General procedure for the synthesis of thioridazine derivatives 4a-c 
The 2-(methylthio)-10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine 3 (0.14 mmol, 1 eq.) was 
added to a round bottomed flask containing a solution of the appropriate aldehyde/ketone 
(0.21 mmol, 1.5 eq.) in THF (5 mL). The solution was then allowed to stir at room 
temperature for 30 minutes. Then, NaBH(AcO)3 (0.28 mmol, 2 eq.) was added and the 
reaction was allowed to react for 24h at r.t.. The reaction was quenched with (20mL) NaOH 
1N solution and the resulting mixture was allowed to stir for 20 minutes. Then the organic 
solvent was removed under reduced pressure evaporation. The residue was added with 
EtOAc and extracted (3 x 10 mL) and finally dried over anhydrous MgSO4. The crude 
products 4a-c were purified by chromatography on silica gel, using EtOAc/MeOH/TEA 
(3.9:1:0.1) as eluent.  
10-(2-(1-Benzylpiperidin-2-yl)ethyl)-2-(methylthio)-10H-phenothiazine (4a): Yield: 67%. 
1
H NMR (400 MHz CDCl3) δ 7.28-7.17 (m, 5H) 7.14-7.10 (m, 2H), 7.03 (d, J = 4.0 Hz, 1H), 
6.92-6.84 (m, 2H), 6.81 (d, J = 4.0 Hz, 2H), 3.97-3.83 (m, 3H), 3.32 (d, J = 8.0 Hz, 1H), 
2.75-2.70 (m, 1H), 2.60-2.55 (m, 1H), 2.43 (s, 3H), 2.14 (s, 2H), 2.00-1.94 (m, 1H), 1.77-
1.41 (m, 6H) ppm. 
13
C NMR (100 MHz CDCl3) δ 146.0, 145.1, 139.7, 137.6, 129.1, 128.8, 
128.6, 128.3, 127.6, 127.6, 127.3, 126.8 125.4, 122.6, 122.3, 120.9, 115.8, 114.7, 58.4, 57.7, 
55.7, 50.6, 44.2, 29.6, 24.4, 23.1, 16.6 ppm. LRMS m/z (ES+) m/z: 447 [M+H]
+
. HRMS 
(ESI) m/z calcd. For C27H31N2S2 [M +H] 447.1923, found 447.1913. 
2-(Methylthio)-10-(2-(1-propylpiperidin-2-yl)ethyl)-10H-phenothiazine (4b): Yield: 
62%. 
1
H NMR (400 MHz CDCl3) δ 7.15-7.11 (m, 2H), 7.03 (d, J = 4.0 Hz, 1H), 6.92-6.88 
(m, 2H), 6.80 (d, J = 4.0 Hz, 2H), 3.94-3.99 (m, 1H), 3.83-3.79 (m, 1H), 2.82-2.77 (m, 1H), 
2.51-2.48 (m, 2H), 2.45 (s, 3H), 2.33-2.22 (m, 2H), 2.16-2.06 (m, 1H), 1.85-1.56 (m, 4H), 
1.43-1.29 (m, 5H), 0.75 (t, J = 8.0 Hz, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 145.8, 145.0, 
137.6, 127.6, 127.5, 127.3, 125.4, 122.6, 122.3, 120.9, 115.8, 114.7, 57.9, 55.7, 51.4, 44.4, 
30.2, 27.9, 25.2, 23.3, 18.9, 16.6, 12.0 ppm. LRMS m/z (ES+) m/z: 399 [M+H]
+
. HRMS 
(ESI) m/z calcd. for C23H31N2S2 [M +H] 399.1923, found 399.1916. 
Synthesis of 10-(2-(1-isopropylpiperidin-2-yl)ethyl)-2-(methylthio)-10H-phenothiazine 
(4c): Yield: 68%. 
1
H NMR (400 MHz CDCl3) δ 7.15-7.11 (m, 2H), 7.03 (d, J = 4.0 Hz, 1H), 
6.92-6.88 (m, 2H), 6.80 (d, J = 4.0 Hz, 2H), 3.96-3.98 (m, 1H), 3.83-3.79 (m, 1H), 3.15 (t, J 
= 8.0 Hz, 1H), 2.81-2.75 (m, 1H), 2.62-2.59 (m, 1H), 2.44 (s, 3H), 2.20-2.03 (m, 2H), 1.85-
1.24 (m, 7H), 1.05 (d, J = 8.0 Hz, 3H), 0.77 (d, J = 8.0 Hz, 3H) ppm. 
13
C NMR (100 MHz 
CDCl3) δ 145.8, 127.6, 127.5, 127.3, 122.6, 120.9, 115.7, 114.7, 56.1, 44.1, 43.9, 31.0, 28.5, 
26.0, 24.0, 21.8, 16.6, 13.9 ppm. LRMS m/z (ES+) m/z: 399 [M+H]
+
. HRMS (ESI) m/z 
calcd. for C23H31N2S2 [M +H] 399.1923, found 399.1916. 
 
General procedure for the synthesis of compound (6a-c) 
The appropriate 2-substituted phenothiazine 5a-c (0.42 mmol, 1eq.) was added to 5 mL of 
DMF in a double neck round bottomed flask. NaH (0.46 mmol, 1.1 eq.) was added to the 
stirring solution at 0°C, and the mixture was allowed to reach r.t stirring for 20 minutes. 
Then, 1-bromo-3-chloropropane (0.46 mmol 1.1eq) was added to the stirring solution. The 
reaction mixture was allowed to stir under N2 atmosphere for 12h at r.t. before being 
quenched with 10 mL of water and extracted twice with 20 mL of EtOAc. The combined 
organic layers were washed with brine (10 mL), dried over Na2SO4 and concentrated under 
reduced pressure giving a yellow-brown crude oil. The obtained product was purified by 
chromatography on silica gel, using hexane/EtOAc (4:1) as eluent.  
10-(3-Chloropropyl)-2-(methylthio)-10H-phenothiazine (6a): Yield: 93%. 
1
H NMR (400 
MHz CDCl3) δ 7.18-7.14 (m, 2H), 7.06 (d, J = 8.0 Hz, 1H), 6.95-6.88 (m, 2H), 6.84-6.81 (m, 
2H), 4.06 (t, J = 8.0 Hz, 2H), 3.65 (t, J = 8.0 Hz, 2H), 2.46 (s, 3H), 2.22 (t, J = 8.0 Hz, 2H) 
ppm. 
13
C NMR (100 MHz CDCl3) δ 145.6, 145.9, 137.8, 127.8, 127.7, 127.5, 125.8, 123.0, 
122.7, 121.1, 115.9, 114.6, 44.1, 42.5, 29.7, 16.5 ppm. LRMS m/z (ES+) m/z: 322 [M+H]
+
. 
2-Chloro-10-(3-chloropropyl)-10H-phenothiazine (6b): Yield: 84%. 
1
H NMR (400 MHz 
CDCl3) δ 7.19-7.14 (m, 2H) 7.04 (d, J = 8.0 Hz, 1H), 6.95 (t, J = 8.0 Hz, 1H), 6.91-6.88 (m, 
2H), 6.86 (s, 1H), 4.04 (t, J = 8.0 Hz, 2H), 3.65 (t, J = 8.0 Hz, 2H), 2.25-2.18 (m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 146.5, 144.4, 133.4, 128.2, 127.8, 127.6, 125.5, 124.2, 123.3, 
122.7, 116.0, 115.9, 44.1, 42.3, 29.5 ppm. LRMS m/z (ES+) m/z: 332 [M+Na]
+
 
10-(3-Chloropropyl)-10H-phenothiazine (6c): Yield: 82%. 
1
H NMR (400 MHz CDCl3) δ 
7.19-7.15 (m, 4H), 6.96-6.89 (m, 4H), 4.07 (t, J = 8.0 Hz, 2H), 3.66 (t, J = 8.0 Hz, 2H), 2.23 
(t, J = 8.0 Hz, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 145.2, 127.8, 127.4, 125.8, 122.9, 
115.7, 44.0, 42.6, 29.7 ppm. LRMS m/z (ES+) m/z: 276 [M+H]
+
 
 
General procedure for the synthesis of thioridazine derivatives (7a-i) 
The appropriate chloro derivative 6a-c (0.18 mmol, 1 eq.) was dissolved in a round bottomed 
flask containing dry DMF (10 mL) and DIPEA (0.19 mmol, 1.1 eq.). The appropriate amine 
(N-substituted piperazine or thiomorpholine) (0.72 mmol, 4 eq.) was then added to the 
solution followed by NaI (5 mg, 0.036 mmol, 0.2 eq.). The mixture was left under N2 
atmosphere at 150 °C for 3 h, after which time it was added with water (10 mL) and extracted 
twice with EtOAc (20 mL). The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure. The obtained product was purified by 
chromatography on silica gel, using EtOAc/MeOH/TEA (3.9:1:0.1) as eluent. 
10-(3-(4-Methylpiperazin-1-yl)propyl)-10H-phenothiazine (7a):[28] Yield: 99%. 
1
H 
NMR (400 MHz CDCl3) δ 7.12 (t, J = 8.0 Hz, 4H), 6.90 (t, J = 8.0 Hz, 4H), 3.90 (t, J = 8.0 
Hz, 2H), 2.46 (t, J = 8.0 Hz, 2H), 2.42-2.34 (m, 8H), 2.26 (s, 3H), 1.94 (d, J = 8.0 Hz, 2H) 
ppm. 
13
C NMR (100 MHz CDCl3) δ 145.2, 127.5, 127.3, 125.1, 122.5, 115.6, 55.7, 55.1, 
53.2, 46.0, 45.4, 24.5 ppm. LRMS m/z (ES+) m/z: 340 [M+H]
+
.  
10-(3-(4-Phenylpiperazin-1-yl)propyl)-10H-phenothiazine (7b): Yield: 62%. 
1
H NMR 
(400 MHz CDCl3) δ 7.25 (t, J = 8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 4H), 6.92-6.88 (m, 6H), 
6.84 (t, J = 8.0 Hz, 1H), 3.95 (t, J = 8.0 Hz, 2H), 3.14 (t, J = 8.0 Hz, 4H), 2.57 (t, J = 8.0 Hz, 
4H), 2.53 (t, J = 8.0 Hz, 2H), 2.02-1.95 (m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 151.4, 
145.3, 129.2, 127.5, 127.3, 125.2, 122.5, 119.7, 116.1, 115.6, 55.7, 53.4, 49.2, 45.3, 24.4 
ppm. LRMS m/z (ES+) m/z: 402 [M+H]
+
. HRMS (ESI) m/z calcd. for C25H28N3S [M +H] 
402.1998, found 402.1995. 
10-(3-(4-Methylpiperazin-1-yl)propyl)-2-(methylthio)-10H-phenothiazine (7c): Yield: 
99%. 
1
H NMR (400 MHz CDCl3) δ 7.11-7.09 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.90-6.85 
(m, 2H), 6.80-6.77 (m, 2H), 3.89 (t, J = 8.0 Hz, 2H), 2.50-2.33 (m, 8H), 2.46 (t, J = 8.0 Hz, 
2H), 2.44 (s, 3H), 2.26 (s, 3H), 1.94-1.92 (m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 145.2, 
144.9, 137.5, 127.6, 127.5, 127.3, 125.2, 122.6, 122.2, 120.8, 115.8, 114.7, 55.6, 55.1, 53.2, 
46.0, 45.3, 24.4, 16.6 ppm. LRMS m/z (ES+) m/z: 386 [M+H]
+
. HRMS (ESI) m/z calcd. for 
C21H28N3S2 [M +H] 386.1719, found 386.1739. 
2-(Methylthio)-10-(3-(4-phenylpiperazin-1-yl)propyl)-10H-phenothiazine (7d): Yield: 
77%. 
1
H NMR (400 MHz CDCl3) δ 7.24 (t, J = 8.0 Hz, 2H), 7.12 (d, J = 8.0 Hz, 2H), 7.03 
(d, J = 8.0 Hz, 1H), 6.92-6.88 (m, 4H), 6.85-6.80 (m, 3H), 3.94 (t, J = 8.0 Hz, 2H), 3.14 (t, J 
= 8.0 Hz, 4H), 2.56 (t, J = 8.0 Hz, 4H), 2.51 (t, J = 8.0 Hz, 2H), 2.45 (s, 3H), 1.99-1.96 (m, 
2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 151.4, 145.7, 145.02, 137.6, 129.2, 127.6, 127.5, 
127.3, 125.3, 122.7, 122.3, 120.9, 119.7, 116.1, 115.8, 114.8, 55.7, 53.4, 49.2, 45.3, 24.4, 
16.6 ppm. LRMS m/z (ES+) m/z: 448 [M+H]
+
. HRMS (ESI) m/z calcd. for C26H30N3S2 [M 
+H] 448.1876, found 448.1866. 
2-(Methylthio)-10-(3-thiomorpholinopropyl)-10H-phenothiazine (7e): Yield: 99%. 
1
H 
NMR (400 MHz CDCl3) δ 7.14-7.03 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.91-6.86 (m, 2H), 
6.80-6.77 (m, 2H), 3.90 (t, J = 8.0 Hz, 2H), 2.63-2.57 (m, 8H), 2.45 (s, 3H), 1.89 (t, J = 8.0 
Hz, 2H) 1.34-1.22 (m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 145.7, 144.9, 137.6, 127.6, 
127.5, 127.3, 122.6, 122.2, 120.8, 115.9, 114.8, 56.1, 55.2, 45.1, 28.1, 24.1, 16.6 ppm. 
LRMS m/z (ES+) m/z: 389 [M+H]
+
. HRMS (ESI) m/z calcd. for C20H25N2S3 [M +H] 
389.1174, found 389.1172. 
10-(3-(4-Adamantan-1-yl)piperazin-1-yl)propyl)-2-(methylthio)-10H-phenothiazine (7f): 
Yield: 71%. 
1
H NMR (400 MHz CDCl3) δ 7.17-7.07 (m, 2H), 7.02 (d, J = 7.8 Hz, 1H), 6.92-
6.85 (m, 2H), 6.84-6.76 (m, 2H), 3.89 (t, J = 6.9 Hz, 2H), 2.56-2.26 (m, 12H), 2.07-1.88 (m, 
8H), 1.88-1.74 (m, 4H), 1.71-1.53 (m, 4H), 1.35 (d, J = 11.9 Hz, 2H) ppm. 
13
C NMR (100 
MHz CDCl3) δ 145.8, 144.9, 137.6, 127.6, 127.5, 127.3, 125.3, 122.7, 122.3, 120.8, 115.9, 
114.7, 55.4, 54.3, 53.2, 46.7, 45.4, 45.2, 44.0, 43.9, 41.0, 38.7, 38.0, 36.8, 36.7, 29.7, 24.3, 
16.6 ppm. LRMS m/z (ES+) m/z: 506 [M+H]
+
. HRMS (ESI) m/z calcd. for C30H40N3S2 [M 
+H] 506.2658, found 506.2644. 
10-(3-(4-(Adamantan-2-yl)piperazin-1-yl)propyl)-2-(methylthio)-10H-phenothiazine 
(7g): Yield: 72%. 
1
H NMR (400 MHz CDCl3) δ 7.15-7.04 (m, 2H), 7.01 (d, J = 7.8 Hz, 1H), 
6.92-6.81 (m, 2H), 6.81 - 6.73 (m, 2H), 3.87 (t, J = 6.6 Hz, 2H), 3.58-3.41 (m, 1H), 3.38-3.25 
(m, 1H), 2.70 (s, 3H), 2.64-2.59 (m, 2H), 2.59-2.55 (m, 2H), 2.55-2.49 (m, 2H), 2.49-2.44 
(m, 3H), 2.43 (s, 3H), 2.07 (m, 5H), 1.97-1.87 (m, 2H), 1.73 (m, 5H), 1.64 (d, J = 2.3 Hz, 3H) 
ppm. 
13
C NMR (100 MHz CDCl3) δ 145.8, 144.9, 137.6, 127.6, 127.5, 127.3, 125.2, 122.6, 
122.2, 120.8, 115.8, 114.7, 67.8, 56.0, 54.0, 49.6, 45.6, 40.6, 37.9, 37.3, 31.4, 29.1, 28.9, 
27.6, 27.4, 24.4, 16.6 ppm. LRMS m/z (ES+) m/z: 506 [M+H]
+
. HRMS (ESI) m/z calcd. for 
C30H40N3S2 [M +H] 506.2658, found 506.2648. 
2-Chloro-10-(3-(4-phenylpiperazin-1-yl)propyl)-10H-phenothiazine (7h): Yield: 57%. 
1
H 
NMR (400 MHz CDCl3) δ 7.24 (t, J = 8.0 Hz, 2H), 7.17-7.11 (m, 2H), 7.01 (d, J = 8.0 Hz, 
1H), 6.94-6.63 (m, 7H), 3.92 (t, J = 8.0 Hz, 2H), 3.15 (t, J = 8.0 Hz, 4H), 2.57 (t, J = 8.0 Hz, 
4H), 2.51 (t, J = 8.0 Hz, 2H), 2.00-1.96 (m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 151.4, 
146.6, 144.6, 133.3, 129.2, 128.0, 127.6, 127.5, 124.8, 123.6, 123.0, 122.3, 119.8, 116.1, 
115.9, 55.6, 53.5, 49.2, 45.4, 24.3 ppm. LRMS m/z (ES+) m/z: 436 [M+H]
+
. HRMS (ESI) 
m/z calcd. For [M +H], found. 
2-Chloro-10-(3-thiomorpholinopropyl)-10H-phenothiazine (7i): Yield: 90% 
1
H NMR 
(400 MHz CDCl3) δ 7.15-7.08 (m, 2H), 6.99 (d, J = 8.0 Hz, 1H), 6.93-6.81 (m, 4H), 3.88 (t, J 
= 8.0 Hz, 2H), 2.66-2.57 (m, 8H), 2.45 (t, J =8.0 Hz, 2H), 1.91-1.85 (m, 2H) ppm. 
13
C NMR 
(100 MHz CDCl3) δ 146.5, 144.6, 133.2, 127.9, 127.6, 127.5, 124.8, 123.5, 122.9, 122.3, 
115.9, 56.0, 55.8, 45.1, 28.1, 24.0 ppm. LRMS m/z (ES+) m/z: 377 [M+H]
+
. HRMS (ESI) 
m/z calcd. For [M +H], found. 
 
2-Chloro-1-(2-(methylthio)-10H-phenothiazin-10-yl)ethanone (8) 
The phenothiazine 5a (1.22 mmol, 1 eq.) was dissolved to 15 mL of DMF in a double neck 
round bottomed flask. NaH (1.83 mmol, 1.5 eq.) was added to the stirring solution at 0°C, 
which then was allowed to reach r.t. under stirring for 20 minutes. Then, 2-chloroacetyl 
chloride (3.66 mmol 3 eq.) was added and the reaction mixture was stirred under N2 
atmosphere for 3h at r.t.. The reaction mixture was then quenched with water (10 mL) and 
extracted twice with EtOAc (20 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure giving a yellow-brown crude oil. 
The obtained product was purified by chromatography on silica gel, using hexane/EtOAc 
(3:2) as eluent.  
Yield: 58%. 
1
H NMR (400 MHz CDCl3) δ 7.53 (d, J = 8.0 Hz, 1H), 7.47-7.43 (m, 2H), 7.36-
7.31 (m, 2H), 7.27-7.23 (m, 1H), 7.14-7.11 (m, 1H), 4.16 (d, J = 8.0 Hz, 2H), 2.49 (s, 3H) 
ppm. 
13
C NMR (100 MHz CDCl3) δ 166.3, 138.8, 138.3, 137.5, 128.3, 128.2, 127.7, 127.5, 
126.5, 125.7, 124.1, 40.7, 15.9 ppm. LRMS m/z (ES+) m/z: 322 [M+H]
+
.  
 Synthesis of 2-(4-methylpiperazin-1-yl)-1-(2-(methylthio)-10H-phenothiazin-10-
yl)ethanone (9a) 
The 1-methylpiperazine (0.63 mmol, 4 eq.) was dissolved in a round bottomed flask 
containing dry DMF (5 mL) and DIPEA (0.17 mmol, 1.1 eq.) The mixture was stirred at r.t 
for 20 minutes, then, 2-chloro-1-(2-(methylthio)-10H-phenothiazin-10-yl)ethanone (8) (0.15 
mmol, 1 eq.) was added to the solution followed by NaI (0.03 mmol, 0.2 eq.). The mixture 
was left under N2 atmosphere at 153 °C for 3 h. Then, the reaction mixture was quenched 
with water (10 mL) and extracted twice with EtOAc (20 mL). The combined organic layers 
were washed with brine, dried over Na2SO4 and concentrated under reduced pressure giving a 
yellow-brown crude oil. The obtained product was purified by chromatography on silica gel, 
using EtOAc/MeOH/TEA (3.9:1:0.1) as eluent.  
Yield: 96%. 
1
H NMR (400 MHz CDCl3) δ 7.51-7.47 (m, 2H), 7.41 (d, J = 8.0 Hz, 1H), 7.32-
7.26 (m, 2H), 7.22-7.18 (m, 1H), 7.10-7.08 (m, 1H), 3.30-3.31 (m, 2H), 2.47 (s, 3H), 2.44-
2.27 (8H), 2.22 (s, 3H) ppm. 
13
C NMR (100 MHz CDCl3) δ 168.6, 139.3, 138.6, 137.9, 
128.0, 127.9, 127.0, 126.9, 125.1, 124.9, 60.4, 54.9, 52.9, 45.9, 16.2 ppm. LRMS m/z (ES+) 
m/z: 386 [M+H]
+
. HRMS (ESI) m/z calcd.  for C20H24N3S2O [M +H], 386.1355 found 
386.1351. 
 
Synthesis of 1-(2-(methylthio)-10H-phenothiazin-10-yl)-2-(piperidin-1-yl)ethanone (9b) 
Piperidine (1.22 mmol, 4 eq.) was added to a round bottomed flask containing DMF (5 mL) 
and DIPEA (0.31 mmol, 1 eq.) and the mixture was allowed to stir at room temperature for 
30 minutes before 2-chloro-1-(2-(methylthio)-10H-phenothiazin-10-yl)ethanone (8) (0.31 
mmol, 1 eq.) was added to the solution. The reaction was allowed to stir for 3h at 150 °C. The 
reaction mixture was then quenched with water (10 mL) and extracted twice with EtOAc (20 
mL). The combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure giving a yellow-brown crude oil. The obtained product 
was purified by chromatography on silica gel, using EtOAc/MeOH/TEA (3.9:1:0.1) as eluent.  
Yield: 91% 
1
H NMR (400 MHz CDCl3) δ 7.51-7.47 (m, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.30-
7.24 (m, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 12.0 Hz, 2H), 3.24-3.23 (d, J = 8.0 Hz, 
2H), 2.47 (s, 3H), 2.35 (m, 4H), 1.46-1.41 (m, 4H), 1.32-1.29 (m, 2H) ppm. 
13
C NMR (100 
MHz CDCl3) δ 163.7, 138.9, 135.8, 135.7, 132.3, 132.2, 126.7, 126.7, 122.2, 118.0, 116.2, 
56.8, 56.1, 25.2, 24.2, 16.0 ppm. LRMS m/z (ES+) m/z: 371 [M+H]
+ 
HRMS (ESI) m/z 
calcd. For [M +H], found. 
 
Synthesis of t-butyl 2-(2-bromoethyl)piperidine-1-carboxylate (11)  
The 2-(piperidin-2-yl)ethanol 10 (1.55 mmol 1 eq.) was added to 10 mL mixture (1:1) of 
CH2Cl2 and Na2CO3 aqueous solution (10 mL) in a round bottomed flask. Di-t-butyl 
dicarbonate (1.70 mmol, 1.1 eq.) was added to the stirring solution. The reaction mixture was 
stirred for 24h at room temperature. Then, the reaction mixture was diluted with 10 mL of 
water and extracted once with 10 mL of CH2Cl2 and twice with 20 mL of EtOAc. The 
combined organic layers were washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure giving a yellow crude oil. The crude product was purified by 
chromatography on silica gel, using hexane/EtOAc (3:2) as eluent affording the N-Boc-
protected amino alcohol. Yield: 98% 
1
H NMR (400 MHz CDCl3) δ 4.35-4.19 (m, 1H) 3.85-
3.80 (m, 2H), 3.48-3.42 (m, 1H), 3.27 (br s, 1H), 2.59-2.52 (m, 1H), 1.81 (t, J = 12.0 Hz, 
1H), 1.64-1.54 (m, 1H), 1.51-1.37 (m, 5H), 1.37 (s, 9H), 1.29-1.25 (m, 1H) ppm. 
13
C NMR 
(100 MHz CDCl3) δ 155.0, 80.2, 58.7, 46.1, 39.4, 32.5, 28.5, 28.4, 25.6, 19.0 ppm. LRMS 
m/z (ES+) m/z: 230 [M+Na]
+ 
 
To a solution of the above synthesised N-Boc-amino alcohol (0.43 mmol 1eq.) in CH2Cl2 (10 
mL) was added PPh3 (0.47 mmol, 1.1 eq.) followed by a solution of CBr4 (0.47mmol, 1.1 eq.) 
in 20 mL of CH2Cl2 at r.t. and the mixture was allowed to stir for 45 min. Then, the reaction 
mixture was concentrated under reduced pressure giving a yellow crude oil. The obtained 
product was then immediately purified by chromatography on silica gel, using hexane/EtOAc 
(9:1) as eluent. The pure product 11 was obtained as a yellow oil. Yield: 79% 
1
H NMR (400 
MHz CDCl3) δ 4.35-4.31 (m, 1H) 4.02-3.84 (m, 1H), 3.33-3.19 (m, 2H), 2.70-2.64 (t, J = 
12.0 Hz, 1H), 2.33-2.23 (m, 1H), 1.90-1.64 (m, 1H), 1.63-1.43 (m, 5H), 1.40 (s, 9H), 1.38-
1.31 (m, 1H) ppm. 
13
C NMR (100 MHz CDCl3) δ 155.2, 79.6, 49.5, 38.7, 33.6, 30.3, 28.7, 
28.5, 25.5, 19.2 ppm. LRMS m/z (ES+) m/z: 293 [M+H]
+
 
General procedure for the synthesis of Boc-protected thioridazine derivatives (S12a-e)  
The appropriate 2-substituted phenothiazine (5a-c) or carbazole, indole, or benzimidazole 
(0.42 mmol, 1eq.) was added to 10 mL of DMF in a double neck round bottomed flask. NaH 
(0.52 mmol, 1.2 eq.) was added to the stirring solution at 0°C, which then was allowed to 
reach r.t stirring for 20 minutes. Then, t-butyl 2-(2-bromoethyl)piperidine-1-carboxylate (11) 
(0.52 mmol 1.2eq.) and NaI (0.02 mmol, 0.1eq) were added to the stirring solution. The 
reaction mixture was allowed to stir under N2 atmosphere for 12h at r.t. Then, the reaction 
mixture was quenched with 20 mL of water and extracted twice with 20 mL of EtOAc. The 
combined organic layers were washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure giving a yellow-brown crude oil. The crude product was purified by 
chromatography on silica gel, using hexane/EtOAc (4:1) as eluent. 
t-Butyl 2-(2-(10H-phenothiazin-10-yl)ethyl)piperidine-1-carboxylate (S12a): Yield: 45%. 
1
H NMR (400 MHz CDCl3) δ 7.16-7.12 (m, 4H), 6.93-6.89 (m, 2H), 6.84 (d, J = 8.0 Hz, 
2H), 4.45-4.35 (m, 1H), 4.08-3.96 (m, 1H), 3.92-3.74 (m, 2H), 3.38-3.28 (m, 1H), 2.83-2.69 
(m, 1H), 2.37-2.18 (m, 1H), 1.91-1.85 (m, 1H), 1.67-1.49 (m, 5H), 1.40 (s, 9H) ppm. 
13
C 
NMR (100 MHz CDCl3) δ 155.1, 145.3, 127.6, 127.3, 125.1, 122.5, 115.3, 79.4, 49.5, 38.7, 
33.6, 30.3, 28.7, 28.5, 25.5, 19.2 ppm. LRMS m/z (ES+) m/z: 411 [M+H]
+
 
t-Butyl 2-(2-(2-chloro-10H-phenothiazin-10-yl)ethyl)piperidine-1-carboxylate (S12b): 
Yield: 61%. 
1
H NMR (400 MHz CDCl3) δ 7.17-7.11 (m, 2H) 7.02 (d, J = 8.0 Hz, 1H), 6.95-
6.83 (m, 3H), 6.78 (d, J = 4.0 Hz, 1H), 4.44-4.39 (m, 1H), 4.38-4.35 (m, 1H), 4.05-4.00 (m, 
1H), 3.88-3.79 (m, 2H), 2.78 (t, J = 12 Hz, 1H), 2.22-2.16 (m, 1H), 1.90-1.81 (m, 1H), 1.68-
1.45 (m, 5H), 1.42 (s, 9H) ppm. 
13
C NMR (100 MHz CDCl3) δ 155.2, 146.7, 144.6, 133.4, 
128.1, 127.5, 124.9, 123.0, 122.4, 115.7, 79.6, 48.8, 44.8, 39.1, 29.3, 28.5, 27.7, 25.6, 19.3 
ppm. LRMS m/z (ES+) m/z: 468 [M+Na]
+  
t-Butyl 2-(2-(9H-carbazol-9-yl)ethyl)piperidine-1-carboxylate (S12c): Yield: 61% 
1
H 
NMR (400 MHz CD3OD) δ 8.37 (d, J = 7.8 Hz, 2H), 7.87-7.64 (m, 4H), 7.60-7.35 (m, 2H), 
4.74 (m, 1H), 4.69-4.59 (m, 1H), 4.36-4.18 (m, 1H), 3.69-3.60 (m, 2H), 3.10-3.07 (m, 1H), 
2.73-2.53 (m, 1H), 2.22 (m, 1H), 2.00-1.86 (m, 5H), 1.85-1.76 (m, 9H) ppm. 
13
C NMR (100 
MHz CD3OD) δ 155.8, 140.6, 140.5, 125.9, 125.6, 123.4, 123.3, 120.4, 120.0, 119.1, 118.7, 
110.8, 108.7, 80.1, 78.6, 40.2, 33.2, 28.5, 27.9, 27.8, 25.7, 19.1, 19.0 ppm. LRMS m/z (ES+) 
m/z: 401 [M+Na]
+
 
t-Butyl 2-(2-(1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (S12d): Yield: 
63% 
1
H NMR (400 MHz CDCl3) δ 7.91 (s, 1H), 7.84-7.67 (m, 1H), 7.39-7.31 (m, 1H), 7.31-
7.09 (m, 2H), 4.49-4.19 (m, 1H), 4.10-3.90 (m, 2H), 2.81-2.65 (m, 1H), 2.38-2.18 (m, 1H), 
1.96-1.77 (m, 1H), 1.72-1.44 (m, 7H), 1.44-1.29 (m, 9H) ppm.
 13
C NMR (100 MHz CDCl3) δ 
155.2, 144.0, 143.2, 133.7, 122.9, 122.1, 120.6, 109.5, 79.9, 60.4, 42.4, 30.1, 28.9, 28.5, 25.5, 
19.2, 14.2 ppm. LRMS m/z (ES+) m/z: 330 [M+H]
+
 
t-Butyl 2-(2-(1H-indol-1-yl)ethyl)piperidine-1-carboxylate (S12e): Yield: 42%. 
1
H NMR 
(400 MHz CDCl3) δ 7.62 (d, J = 8.0 Hz, 1H) 7.31 (d, J = 8.0 Hz, 1H), 7.22-7.18 (m, 1H), 
7.12-7.07 (m, 2H), 6.48 (d, J = 4.0 Hz, 1H), 4.38-4.33 (m, 1H), 4.15-4.03 (m, 3H), 2.81 (t, J 
= 8.0 Hz, 1H), 2.31-2.21 (m, 1H), 1.93-1.86 (m, 1H), 1.68-1.58 (m, 6H), 1.45 (s, 9H) ppm 
13
C NMR (100 MHz CDCl3) δ 155.2, 135.8, 128.8, 127.9, 121.5, 121.1, 119.4, 109.2, 101.2, 
79.7, 43.8, 30.7, 29.0, 28.6, 25.6, 19.2 ppm. LRMS m/z (ES+) m/z: 352 [M+Na]
+
 
 
General procedure for the synthesis of thioridazine derivatives (12a-e) 
The appropriate Boc-protected compound (S12a-e) (0.24 mmol, 1 eq.) was added to a round 
bottom flask containing 5 ml HCl saturated solution in EtOAc. The reaction mixture was 
allowed to stir at room temperature for 24h. The solvent was removed under reduced pressure 
giving a white solid as product of the reaction. The solid products 12a-e were washed several 
times with cold Et2O. 
10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine (12a): Yield: 99% 
1
H NMR (400 MHz 
CDCl3) δ  9.41 (br. s., 1H), 9.24 (br. s., 1H), 7.15-7.12 (m, 4H), 6.92-6.86 (m, 4H), 3.97-3.92 
(m, 2H), 3.49-3.45 (m, 1H), 3.08-3.05 (m, 1H), 2.73-2.57 (m, 1H), 2.45-2.43 (m, 1H), 2.18-
2.06 (m, 1H), 1.93-1.74 (m, 3H), 1.69-1.60 (m, 2H), 1.44-1.34 (m, 1H) ppm. 
13
C NMR (100 
MHz CDCl3) δ 145.3, 127.7, 127.4, 125.4, 122.7, 115.6, 55.6, 46.8, 44.3, 33.7, 32.4, 25.9, 
24.5 ppm. LRMS m/z (ES+) m/z: 312 [M+H]
+
 
Synthesis of 2-chloro-10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine (12b): Yield: 94% 
1
H NMR (400 MHz CDCl3) δ 9.54 (br s, 1H), 9.34 (br s, 1H), 7.19 (t, J = 8.0Hz 1H), 7.13 (d, 
J = 8.0 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.95-6.89 (m, 4H), 4.07-3.96 (m, 2H), 3.31 (d, J = 
8.0 Hz, 1H), 3.12-3.04 (m, 1H), 2.77-2.68 (m, 1H), 2.50-2.42 (m, 1H), 2.13-2.09 (m, 1H), 
1.85-1.69 (m, 6H) ppm. 
13
C NMR (100 MHz CDCl3) δ 146.6, 144.5, 133.3, 128.0, 127.6, 
127.5, 125.1, 123.9, 123.1, 122.5, 115.9, 55.4, 46.7, 44.4, 33.5, 29.7, 25.8, 24.4 ppm. LRMS 
m/z (ES+) m/z: 367 [M+Na]
+
 
Synthesis of 9-(2-(piperidin-2-yl)ethyl)-9H-carbazole (12c): Yield: 95% 
1
H NMR (400 
MHz CDCl3) δ 9.66 (br s, 1H), 9.41 (br s, 1H), 8.02 (d, J = 8.0, 2H), 7.46-7.37 (m, 4H), 7.17 
(t, J = 8.0, 2H), 4.51-4.43 (m, 1H), 4.31-4.25 (m, 1H), 3.38-3.36 (m, 1H), 3.02-2.90 (m, 1H), 
2.70-2.67 (m, 1H), 2.49-2.48 (m, 1H), 2.18-2.12 (m, 1H), 1.88-1.61 (m, 6H) ppm. 
13
C NMR 
(100 MHz CDCl3) δ 140.0, 126.1, 122.9, 120.4, 119.3, 108.8, 55.5, 44.9, 39.5, 32.7, 30.0, 
22.3, 22.0 ppm. LRMS m/z (ES+) m/z: 279 [M+H]
+
 
Synthesis of 1-(2-(piperidin-2-yl)ethyl)-1H-benzo[d]imidazole (12d): Yield: 90% 
1
H 
NMR (400 MHz CDCl3) δ 10.17 (s 1H), 9.68 (br s, 2H), 7.82 (t, J = 8.0 Hz, 2H), 7.44-7.36 
(m, 2H), 5.01-4.79 (m, 2H), 3.46-3.43 (m, 1H), 3.36-3.25 (m, 1H), 2.98-2.94 (m, 1H), 2.85-
2.71 (m, 1H), 2.50-2.36 (m, 1H) 1.90-1.75 (m, 6H) ppm. 
13
C NMR (100 MHz CDCl3) δ 
140.9, 130.7, 126.9, 126.7, 115.6, 112.7, 54.1, 45.0, 43.7, 33.4, 28.7, 22.3, 20.9 ppm. LRMS 
m/z (ES+) m/z: 230 [M+H]
+
 
Synthesis of 1-(2-(piperidin-2-yl)ethyl)-1H-indole (12e): Yield: 94% 
1
H NMR (400 MHz 
CD3OD) δ 7.42-7.34 (m, 1H), 7.24-7.19 (m, 1H), 7.10-7.01 (m, 2H), 6.90-6.80 (m, 2H), 4.12-
4.01 (m, 2H), 3.39-3.24 (m, 1H), 2.95-2.89 (m, 2H), 2.82-2.73 (m, 1H), 2.75-2.59 (m, 1H), 
2.49-2.40 (m, 1H), 2.38-2.29 (m, 2H), 1.84-1.67 (m, 3H) ppm. 
13
C NMR (100 MHz 
(CD3)2SO) δ 135.8, 127.9, 121.8, 121.1, 119.6, 119.1, 109.7, 54.2, 45.2, 43.6, 33.3, 28.8, 
22.1, 20.8 ppm. LRMS m/z (ES+) m/z: 229 [M+H]
+
 
 
General procedure for the synthesis of thioridazine derivatives (13a-d) 
Compounds (12a-d) (0.14 mmol, 1 eq.) were added to a round bottom flask containing THF 
(5 mL) and formaldehyde aqueous solution 37% w/v (0.28 mmol, 2 eq.). The solution was 
then allowed to stir at room temperature for 30 minutes. Then, NaBH(AcO)3 (0.28 mmol, 2.0 
eq.) was added. The reaction was then stirred for 24h at r.t. after which time the solution was 
quenched with (20mL) NaOH 1N aqueous solution. The resulting mixture was stirred for 
further 20 minutes and then the organic solvent was removed through reduced pressure 
evaporation. The residue was diluted with EtOAc, extracted twice with EtOAc (10 mL) and 
dried over anhydrous MgSO4. The solvent was concentrated under reduced pressure and the 
obtained product was purified by chromatography on silica gel, using EtOAc/MeOH/TEA 
(3.9:1:0.1) as eluent.  
10-(2-(1-Methylpiperidin-2-yl)ethyl)-10H-phenothiazine (13a): Yield: 47%. 
1
H NMR 
(400 MHz CDCl3) δ 7.19-7.07 (m, 4H), 6.95-6.85 (m, 4H), 3.95 (ddd, J = 13.9, 8.6, 5.5 Hz, 
1H), 3.89-3.77 (m, 1H), 2.89-2.72 (m, 1H), 2.22-2.16 (m, 3H), 2.16-1.99 (m, 3H), 1.93-1.80 
(m, 1H), 1.71 (d, J = 10.1 Hz, 1H), 1.64-1.50 (m, 2H), 1.34-1.18 (m, 3H) ppm. 
13
C NMR 
(100 MHz CDCl3) δ 145.4, 127.6, 127.3, 125.4, 122.5, 115.6, 62.2, 57.0, 43.9, 43.1, 30.8, 
30.0, 25.7, 24.2 ppm. LRMS m/z (ES+) m/z: 325 [M+H]
+
. HRMS (ESI) m/z calcd. for 
C20H25N2S [M +H] 325.1733,  found 325.1735. 
2-Chloro-10-(2-(1-methylpiperidin-2-yl)ethyl)-10H-phenothiazine (13b): Yield: 38%. 
1
H 
NMR (400 MHz CDCl3) δ 7.11-7.02 (m, 2H), 6.94 (d, J = 8.3 Hz, 1H), 6.85 (t, J = 7.4 Hz, 
1H), 6.82-6.73 (m, 3H), 3.91-3.78 (m, 1H), 3.78-3.63 (m, 1H), 2.85-2.68 (m, 1H), 2.14 (s, 
3H), 2.07-1.95 (m, 3H), 1.85-1.72 (m, 1H), 1.69-1.58 (m, 2H), 1.56-1.46 (m, 2H), 1.28-1.11 
(m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 147.5, 145.2, 133.8, 128.4, 128.1, 127.8, 126.0, 
125.1, 123.6, 122.8, 116.8, 116.5, 62.5, 57.1, 44.4, 42.3, 30.9, 29.7, 25.6, 24.1 ppm. LRMS 
m/z (ES+) m/z: 359 [M+H]
+
. HRMS (ESI) m/z calcd. for C20H24ClN2S [M +H] 359.1343, 
found 359.1347. 
9-(2-(1-Methylpiperidin-2-yl)ethyl)-9H-carbazole (13c): Yield: 67%. 
1
H NMR (400 MHz 
CDCl3) δ 8.10 (d, J = 7.3 Hz, 2H), 7.52-7.32 (m, 4H), 7.29-7.06 (m, 2H), 4.52-4.38 (m, 1H), 
4.38-4.22 (m, 1H), 2.97-2.82 (m, 1H), 2.33 (s, 3H), 2.17-2.06 (m, 2H), 2.06-1.94 (m, 2H), 
1.79 (d, J = 11.9 Hz, 2H), 1.67-1.60 (m, 2H), 1.40-1.27 (m, 2H) ppm 
13
C NMR (100 MHz 
CDCl3) δ 140.2, 125.7, 123.0, 120.5, 118.8, 108.6, 61.7, 57.0, 43.0, 39.2, 31.5, 30.7, 25.6, 
24.4 ppm. LRMS m/z (ES+) m/z: 293 [M+H]
+
. HRMS (ESI) m/z calcd. for C20H24N2 [M 
+H], 293.19 found 293.2014. 
1-(2-(1-Methylpiperidin-2-yl)ethyl)-1H-benzo[d]imidazole (13d): Yield: 70%. 
1
H NMR 
(400 MHz CD3OD) δ 8.86 (s, 1H), 8.33-8.22 (m, 2H), 7.99-7.90 (m, 2H), 5.03-4.95 (m, 2H), 
3.55-3.50 (m, 1H), 2.90 (s, 3H), 2.70-2.42 (m, 4H), 2.28-2.24 (m, 2H), 2.00-1.80 (m, 4H) 
ppm. 
13
C NMR (100 MHz CD3OD) δ 144.0, 143.3, 134.0, 123.7, 122.9, 119.6, 110.7, 62.2, 
57.1, 42.1, 32.8, 30.6, 30.1, 25.4, 24.1 ppm. LRMS m/z (ES+) m/z: 244 [M+H]
+
. HRMS 
(ESI) m/z calcd. for C15H22N3 [M +H] 244.1808, found 244.1811. 
 
Synthesis of 1-(3-chloropropyl)-1H-indole (15) 
Indole (0.52 mmol, 1 eq.) was added to 10 mL of DMF in a double neck round bottomed 
flask. NaH (0.57 mmol, 1.1 eq.) was added to the stirring solution at 0 °C, and the mixture 
was allowed to reach r.t stirring for 20 minutes. Then, 1-bromo-3-chloropropane (0.57 mmol 
1.1 eq.) was added. The reaction mixture was allowed to stir under N2 atmosphere for 12h at 
r.t. The reaction was quenched with water (10 mL) and extracted twice with EtOAc (20 mL). 
The combined organic layers were washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure giving a yellow-brown crude oil. The crude product (15) was purified 
by chromatography on silica gel, using hexane/EtOAc (4:1) as eluent. Yield: 82% 
1
H NMR 
(400 MHz CDCl3) δ 7.69 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.27 (t, J = 8.0 Hz, 
1H), 7.19-7.15 (m, 2H), 6.56 (d, J = 4.0 Hz, 1H), 4.37-4.33 (m, 2H), 3.46 (t, J = 8.0 Hz, 1H), 
3.32 (t, J = 8.0 Hz, 1H), 2.37-2.26 (m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 135.9, 128.8, 
128.1, 121.8, 121.2, 119.6, 109.4, 101.6, 42.9, 42.0, 32.7 ppm. LRMS m/z (ES+) m/z: 194 
[M+H]
+
 
 
Synthesis of 1-(3-(4-methylpiperazin-1-yl)propyl)-1H-indole (16). 
The derivative 16 was synthesised following the procedure used for the synthesis of 
compounds 7a-i. Yield: 63%. 
1
H NMR (400 MHz CDCl3) δ 7.51-7.47 (m, 2H), 7.40 (d, J = 
8.0 Hz, 1H), 7.30-7.24 (m, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 12.0 Hz, 2H), 3.24-3.23 
(d, J = 8.0 Hz, 2H), 2.47 (s, 3H), 2.35 (m, 4H), 1.46-1.41 (m, 4H), 1.32-1.29 (m, 2H) ppm. 
13
C NMR (100 MHz CDCl3) δ 163.7, 138.9, 135.8, 135.7, 132.3, 132.2, 126.7, 126.7, 122.2, 
118.0, 116.2, 56.8, 56.1, 25.2, 24.2, 16.0 ppm. LRMS m/z (ES+) m/z: 258 [M+H]
+ 
HRMS 
(ESI) m/z calcd. for C16H24N3 [M +H] 258.1965, found 258.1966. 
 
4.2 Biology 
Bacterial strains and growth conditions: The bacterial species used in this study were M. 
smegmatis mc2155 (ATCC 700084), M. bovis BCG Pasteur (ATCC 35734), M. 
tuberculosis mc27000, M. tuberculosis H37Rv (ATTC27294), M. tuberculosis CF73 and 
two MDR-TB clinical isolates (CF104 and CF81) obtained from. Mycobacterial species 
were cultured in either Middlebrook 7H9 broth or Middlebrook 7H10 agar media 
supplemented with albumin-dextrose-catalase (ADC) or oleic acid-albumin-dextrose-
catalase (OADC) enrichments, respectively, purchased from BD Biosciences. All reagents 
were purchased from Sigma-Aldrich unless stated otherwise. 
 
Bacterial growth inhibition assays.  
 
The MIC of the compounds against M. smegmatis mc2155, M. bovis BCG, and M. 
tuberculosis mc27000 were calculated by standard MABA (Microplate Alamar Blue 
assay) as previously described.[27] Briefly, 200 µL of sterile deionized water was added to 
all outer-perimeter wells of a sterile 96-well plate (Corning Incorporated, Corning, NY) to 
minimize evaporation of the medium in the test wells during incubation. The wells in rows 
B to G in columns 3 to 11 received 100 µL of 7H9 medium containing 0.2% casamino 
acids, 24 µg/mL pantothenate and 10% OADC (Beckton Dickinson, Sparks, MD). 
Compounds were added to rows B–G followed by 1:2 serial dilutions across the plate to 
column 10, and 100 µL of excess medium was discarded from the wells in column 10. The 
bacterial culture at 0.5 McFarland standard diluted 1:50 (100 µL) was added to the wells in 
rows B to G in columns 2 to 11, where the wells in column 11 served as drug-free 
controls. The plates were sealed with parafilmTM and were incubated at 37 °C. A freshly 
prepared 1:1 mixture of Alamar Blue (Celltiter-Blue™, Promega Corp, Madison, WI) 
reagent and 10% Tween
®
 80 (50 µL) and re-incubated at 37 °C for 24 h. 
 
Determination of Minimal Inhibitory Concentration (MIC90) 
 
The anti-M. tuberculosis activity of the compounds against M. tuberculosis H37Rv 
(ATTC27294), M. tuberculosis CF73 and two MDR-TB clinical isolates (CF104 and 
CF81) was determined using the Resazurin Microtiter Assay (REMA) method according to 
Palomino et al., [29]. Stock solutions of the tested compounds were prepared in dimethyl 
sulfoxide (DMSO), then diluted in Middlebrook 7H9 broth (Difco, Detroit, MI, USA) 
supplemented with oleic acid, albumin, dextrose and catalase (OADC enrichment) to 
obtain a final drug concentration range of 0.09–100 µg/mL. A suspension of the M. 
tuberculosis H37Rv ATCC 27294 and clinical isolates were cultured in Middlebrook 7H9 
broth supplemented with OADC and 0.05% Tween 80 for one week at 37 °C in an 
atmosphere of 5% CO2.. The concentration was adjusted at McFarland 1 and diluted to 2.4 
× 10
5
 CFU/mL. 100 µL of the inoculum was added to each well of a 96-well microplate 
together with 100 µL of the compounds. The plate was incubated for 7 days at 37 °C in an 
atmosphere of 5% CO2. After 24 h, 30 µL 0.01% resazurin (solubilized in water) was 
added. The fluorescence of the wells was read after 24 h using a Cytation 3 (BioTek
®
, 
Winooski, VT, USA). The MIC90 was defined as the lowest concentration resulting in 90% 
inhibition of growth of M. tuberculosis. Samples were set up in three independent assays. 
 
Cytotoxic Analysis (IC50) of MRC-5 cell line 
 
In these experiment, cells were collected in a solution of trypsin/ethylenediamine tetracetic 
acid (EDTA) (Vitrocell
®
) and centrifuged (252× g for 5 min). The number of cells was 
counted using a Neubauer chamber (Celeromics, Valencia, Spain) after staining non-viable 
cells with 0.4% trypan blue solution (Sigma-Aldrich
®
) via the cell exclusion assay. Then, 
the cell concentration was adjusted to 7.5 × 10
4
 cells/mL in DMEM for tumor cells and 
MRC-5 cells (ATCC CCL-171). Next, a 200 μL suspension was deposited into each well 
of a 96-well microplate to a cell density of 1.5 × 10
4
 cells/well. The cells were incubated at 
37 °C in an atmosphere of 5% CO2 for 24 h to allow the cells to attach to the plate [30]. 
The compounds were solubilized in DMSO to an initial concentration of 10,000 µg/mL. 
Test solutions of the compounds were prepared to obtain concentrations from 500 to 1.95 
μg/mL. The diluted solutions were added to the cells after changing the medium to remove 
any non-adherent cells, and the cultures were incubated for an additional 24 h. The 
cytotoxicity of the compounds was determined after incubating the cells in 30 μL of 
resazurin for approximately 2 h. The measurement was performed using a Synergy H1 
microplate reader (BioTek
®
, Winooski, VT, USA) with excitation and emission filters at 
wavelengths of 530 and 590 nm, respectively. The assays were performed in three 
independent experiments. 
 
Efflux pump inhibition assays 
The assay was performed based on previously published protocols.[26] In brief, early log 
phase cells of M. smegmatis were taken and the OD600 was adjusted to 0.4 in 1× PBS. The 
test samples contained (4−6) × 107 bacteria/mL in PBS, 0.4% glucose (as a source of energy 
for efflux pumps activity), 0.5 mg/L ethidium bromide (as a substrate for efflux pumps), and 
the compounds being tested at 1/4× MIC concentrations. Blank samples contained all of the 
components mentioned above, except the bacterial suspension, which was replaced with 1× 
PBS. Verapamil and chlorpromazine, known efflux pump inhibitors, were used as positive 
controls at concentrations of 125 μg/mL and xx respectively. The experiment was performed 
in a 96-well plates that was read in a fluorimeter (FLUOstar OPTIMA, BMG Labtech) with 
the following parameters: wavelengths of 544 and 590 nm for excitation and detection of 
fluorescence, gain 2200, a temperature of 37 °C, and a cycle of measurement every minute 
for a total period of 60 min. The accumulation or efflux of ethidium bromide was monitored 
in real-time for the mentioned period. 
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